3145P A phase II study of participant (pt)-reported preference for pembrolizumab (pembro) administered subcutaneously (SC) or intravenously (IV)
Articles > Article ยท 2025
Authors: I.A. Casarini, D.M. Kowalski, C. Caglevic, S.B. Karaca Yayla, A.T. Sumbul, P.E. Yanez Weber, A.N. Yanzi Castilla, O. Bylicki, T. Takagi, K. McQuarrie, S. Saraf, A. Arunachalam, N. Bhagwati, G.L. Cohen
Annals of Oncology, International, WoS, 2025, vol 36, pp S637-S637